Patents by Inventor Christine Beeton
Christine Beeton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10246496Abstract: Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X?4 is D, E or other negatively-charged amino acid or derivative thereof, X?3 is E, I, L, S, V, W or a tryptophan derivative, X?2 is any amino acid, X?1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety.Type: GrantFiled: August 14, 2015Date of Patent: April 2, 2019Assignees: LA TROBE UNIVERSITY, MONASH UNIVERSITY, BAYLOR COLLEGE OF MEDICINE, PEPTIDES INTERNATIONAL, INC.Inventors: Raymond S. Norton, Shih Chieh Chang, Michael W. Pennington, Christine Beeton, Brian J. Smith
-
Publication number: 20170362286Abstract: Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X?4 is D, E or other negatively-charged amino acid or derivative thereof, X?3 is E, I, L, S, V, W or a tryptophan derivative, X?2 is any amino acid, X?1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety.Type: ApplicationFiled: August 14, 2015Publication date: December 21, 2017Inventors: Raymond S. NORTON, Shih Chieh CHANG, Michael W. PENNINGTON, Christine BEETON, Brian J. SMITH
-
Publication number: 20170274047Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments, the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.Type: ApplicationFiled: February 28, 2017Publication date: September 28, 2017Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BACHEM AMERICAS, INC.Inventors: K. George Chandy, Christine Beeton, Michael William Pennington
-
Patent number: 9708377Abstract: A novel peptide analogue of the Heterometrus spinnifer toxin HsTX1 is disclosed along with its application as, for example, a therapeutic agent for treating an autoimmune disease such as multiple sclerosis (MS) or rheumatoid arthritis (RA). The analogue comprises a peptide with an amino acid substitution at amino acid position 14 of the wild-type (WT) peptide sequence (or a position corresponding to position 14 of the WT peptide sequence). The analogue exhibits selectivity for Kv1.3 over Kv1.1 and other potassium channels relative to the WT peptide.Type: GrantFiled: October 28, 2013Date of Patent: July 18, 2017Assignees: Monash University, Baylor College of Medicine, Peptides International, Inc.Inventors: Raymond S. Norton, Serdar Kuyucak, M Harunur Rashid, Michael Pennington, Christine Beeton
-
Patent number: 9616102Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.Type: GrantFiled: May 28, 2015Date of Patent: April 11, 2017Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BACHEM AMERICAS, INC.Inventors: K. George Chandy, Christine Beeton, William Michael Pennington
-
Publication number: 20160264634Abstract: A novel peptide analogue of the Heterometrus spinnifer toxin HsTX1 is disclosed along with its application as, for example, a therapeutic agent for treating an autoimmune disease such as multiple sclerosis (MS) or rheumatoid arthritis (RA). The analogue comprises a peptide with an amino acid substitution at amino acid position 14 of the wild-type (WT) peptide sequence (or a position corresponding to position 14 of the WT peptide sequence). The analogue exhibits selectivity for Kv1.3 over Kv1.1 and other potassium channels relative to the WT peptide.Type: ApplicationFiled: October 28, 2013Publication date: September 15, 2016Inventors: Raymond S. NORTON, Serdar KUYUCAK, M Harunur RASHID, Michael PENNINGTON, Christine BEETON
-
Publication number: 20160193249Abstract: In some embodiments, the present disclosure pertains to methods of treating an inflammatory disease in a subject by administering a carbon material to the subject. In some embodiments, the carbon material selectively targets T cells in the subject. In some embodiments, the carbon material includes poly(ethylene glycol)-functionalized hydrophilic carbon clusters. In some embodiments, the administration of the carbon material to the subject reduces or inhibits T cell-mediated reactions in the subject. In some embodiments, the carbon material selectively targets T cells over other types of immune cells by preferential uptake into the T cells. In some embodiments, the carbon material reduces or inhibits proliferation of targeted T cells, reduces or inhibits cytokine production by targeted T cells, and reduces intracellular oxidant content in targeted T cells. In some embodiments, the present disclosure pertains to methods of modulating T cells ex-vivo by incubating the T cells with a carbon material.Type: ApplicationFiled: September 3, 2014Publication date: July 7, 2016Inventors: James M. Tour, Christine Beeton, Redwan U. Huq, Taeko Inoue, Robia G. Pautler, Errol L.G. Samuel
-
Publication number: 20160015782Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.Type: ApplicationFiled: May 28, 2015Publication date: January 21, 2016Inventors: K. George Chandy, Christine Beeton, William Michael Pennington
-
Patent number: 9061071Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv 1.3 channels) over other potassium channels (e.g., Kv 1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells.Type: GrantFiled: March 6, 2013Date of Patent: June 23, 2015Assignee: The Regents of the University of CaliforniaInventors: K. George Chandy, Christine Beeton, William Michael Pennington
-
Patent number: 8440621Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells.Type: GrantFiled: November 1, 2011Date of Patent: May 14, 2013Assignees: The Regents of the University of California, Bachem Biosciences, Inc.Inventors: George K. Chandy, Christine Beeton, Michael William Pennington
-
Publication number: 20120142600Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells.Type: ApplicationFiled: November 1, 2011Publication date: June 7, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Christine Beeton, George K. Chandy, Michael William Pennington
-
Patent number: 8080523Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.Type: GrantFiled: October 7, 2005Date of Patent: December 20, 2011Assignee: The Regents of the University of CaliforniaInventors: Christine Beeton, George K. Chandy, Michael William Pennington
-
Publication number: 20080221024Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.Type: ApplicationFiled: October 7, 2005Publication date: September 11, 2008Inventors: George K. Chandy, Christine Beeton, William Michael Pennington